Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 + nivolumab as first-line treatment in gastric cancer with severe peritoneal metastasis
jRCTs041220164Phase 2Active, not recruiting
- Sponsor
- West Japan Oncology Group
- Start
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, oxaliplatin, fluorouracil and levoleucovorin in gastric cancer (GC), gastric adenocarcinoma and peritoneal carcinomatosis (PC), sponsored by West Japan Oncology Group. Primary endpoint: 1-year survival rate. Started May 2023; status: active, not recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastric adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on jRCTs041220164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220164.